kidney disease

[AVM Biotechnology, LLC (Business Wire)] AVM Biotechnology, LLC, announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant. This $1.6 million award from the National Institute of Diabetes and Digestive Kidney Disease will allow the company to pursue additional research in the use of AVM0703 as a monotherapy and combination therapy to reverse recent onset and established Type 1 Diabetes.

[Scientific Reports] The authors described a novel subset of renal perivascular MSCs that expressed Meflin, a glycosylphosphatidylinositol-anchored protein that was recently identified as a marker of fibroblasts essential for cardiac tissue repair.

[Cell Death & Disease] Irisin effectively inhibited β-GP-induced calcium deposition in VSMCs in vitro and in mice aortic rings ex vivo. Overexpression of Nlrp3 attenuated the suppressive effect of Irisin on VSMC calcification.

[Cell Death & Disease] The authors investigated the mechanism of bone marrow MSC-derived exosome using high phosphate stimulated human aortic smooth muscle cells and 5/6 subtotal nephrectomy rat models.

[Scientific Reports] Researchers examined blood–brain barrier disruption, by assessing brain-derived neurotropic factor, neuron-specific enolase levels, and gut-blood barrier disruption by trimethylamine N-oxide in chronic kidney disease patients.

[Critical Journal of the American Society of Nephrology] Extracellular vesicles derived from reparative cells, such as mesenchymal stem cells, tubular epithelial progenitor cells, and human umbilical cord blood represent promising regenerative tools for treatment of kidney diseases.